CN102361876B - 二环杂环螺环化合物 - Google Patents

二环杂环螺环化合物 Download PDF

Info

Publication number
CN102361876B
CN102361876B CN201080013672.6A CN201080013672A CN102361876B CN 102361876 B CN102361876 B CN 102361876B CN 201080013672 A CN201080013672 A CN 201080013672A CN 102361876 B CN102361876 B CN 102361876B
Authority
CN
China
Prior art keywords
compound
indol
dimethyl
pharmaceutically acceptable
decan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080013672.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102361876A (zh
Inventor
A·费舍尔
N·巴纳
V·那楚姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Israel Institute for Biological Research
Original Assignee
Israel Institute for Biological Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel Institute for Biological Research filed Critical Israel Institute for Biological Research
Publication of CN102361876A publication Critical patent/CN102361876A/zh
Application granted granted Critical
Publication of CN102361876B publication Critical patent/CN102361876B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201080013672.6A 2009-01-26 2010-01-26 二环杂环螺环化合物 Active CN102361876B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14714309P 2009-01-26 2009-01-26
US61/147,143 2009-01-26
PCT/IL2010/000064 WO2010084499A2 (en) 2009-01-26 2010-01-26 Bicyclic heterocyclic spiro compounds

Publications (2)

Publication Number Publication Date
CN102361876A CN102361876A (zh) 2012-02-22
CN102361876B true CN102361876B (zh) 2015-02-04

Family

ID=42291285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080013672.6A Active CN102361876B (zh) 2009-01-26 2010-01-26 二环杂环螺环化合物

Country Status (12)

Country Link
US (1) US8673931B2 (enExample)
EP (1) EP2389383B1 (enExample)
JP (2) JP5874878B2 (enExample)
KR (2) KR101675174B1 (enExample)
CN (1) CN102361876B (enExample)
AU (1) AU2010207486B2 (enExample)
BR (1) BRPI1007350B8 (enExample)
CA (1) CA2750777C (enExample)
NZ (1) NZ594768A (enExample)
RU (1) RU2506266C2 (enExample)
WO (1) WO2010084499A2 (enExample)
ZA (1) ZA201106221B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361876B (zh) * 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
JP5909070B2 (ja) * 2010-10-28 2016-04-26 国立大学法人 東京大学 Ｇｓ共役受容体に対する医薬品候補化合物をスクリーニングする方法
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
WO2014113893A1 (en) * 2013-01-28 2014-07-31 University Of Manitoba Use of galantamine and related compounds for treatment of inflammatory bowel diseases
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
RU2604878C1 (ru) * 2015-11-17 2016-12-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" 7-АМИНО-2,2',4-ТРИОКСО-5'-ФЕНИЛ-1,1',2,2',3,4-ГЕКСАГИДРОСПИРО{ПИРАНО[2,3-d]ПИРИМИДИН-5,3'-ПИРРОЛ}-6-КАРБОНИТРИЛЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US12201619B2 (en) 2018-03-22 2025-01-21 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
PE20221453A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR120169A1 (es) * 2019-10-09 2022-02-02 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
CA3183111A1 (en) * 2020-05-12 2021-11-18 Beijing Greatway Pharmaceutical Technology Co., Ltd. Compound for adjusting activity of nmda receptor, and pharmaceutical composition and use thereof
CA3263540A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp Compositions and methods for the prevention of cognitive decline caused by degenerative diseases

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189370A2 (de) * 1985-01-16 1986-07-30 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
EP0205247A2 (en) * 1985-05-10 1986-12-17 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
EP0303391A2 (en) * 1987-08-13 1989-02-15 State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research Optical isomers of a spiroquinuclidine derivative
CN1033629A (zh) * 1987-10-05 1989-07-05 山之内制药株式会社 杂环螺环化合物及其制法
EP0350118A2 (en) * 1988-07-08 1990-01-10 Merck Sharp & Dohme Ltd. Spiro-azabicyclic muscarinic agonists
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
CN1129942A (zh) * 1993-07-20 1996-08-28 以色列国有生物学研究所 作用于胆碱能系统的具有毒蕈碱拮抗性的氮杂螺环化合物
CN1662506A (zh) * 2002-05-03 2005-08-31 以色列生物研究所 治疗中枢和周围神经系统疾病的方法和组合物及其有用的新化合物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
JPS60208590A (ja) * 1984-03-30 1985-10-21 株式会社日立製作所 エレベ−タ−敷居装置
DE3501225A1 (de) * 1985-01-16 1986-07-24 Sandoz-Patent-GmbH, 7850 Lörrach Spirodioxolane, ihre herstellung und verwendung
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
JPS63208590A (ja) * 1987-02-24 1988-08-30 Yamanouchi Pharmaceut Co Ltd ヘテロ環式スピロ化合物及びその製造法
JPS63208844A (ja) * 1987-02-26 1988-08-30 Konica Corp 有機着色物質の光褪色防止方法
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
US4876260A (en) 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US4900830A (en) 1987-10-28 1990-02-13 Israel Institute For Biological Research Process for labelling sulfur-containing compounds
IT1223343B (it) 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
JPH02164882A (ja) 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
CA2050905A1 (en) 1989-02-23 1990-08-24 George R. Felt Therapeutic aerosol formulations
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
EP0590150B1 (en) * 1991-05-15 1998-07-08 Yamanouchi Pharmaceutical Co. Ltd. (-)-(s)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro 4,5]decane l-tartrate
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
EP0801557B1 (en) 1995-10-12 2003-07-02 Supergen, Inc. Liposome formulations of 5beta steroids
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
CN1310612A (zh) 1998-05-20 2001-08-29 利普索姆公司 新型颗粒制剂
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
KR100845769B1 (ko) 1999-02-03 2008-07-11 파우더젝트 리서치 리미티드 하이드로겔 입자 제제
NZ513981A (en) 1999-03-08 2004-02-27 Powderject Res Ltd Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
WO2000062759A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
ES2220724T3 (es) 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Composiciones de peptidos ciclicos administrables por via nasal.
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
ATE364381T1 (de) 2000-04-17 2007-07-15 Vectura Ltd Formulierungen zur verwendung in inhalationsvorrichtungen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2001290678A1 (en) 2000-09-08 2002-03-22 Powderject Research Limited Alginate particle formulation
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
PT1418890E (pt) 2001-08-16 2008-06-09 Baxter Int Formulações de micropartículas à base de propulsor
AU2003215334A1 (en) 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
EP1487411B1 (en) 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalable sustained therapeutic formulations
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
DE10323244A1 (de) 2003-05-22 2004-12-16 Infineon Technologies Ag Integrierte Speicher-Schaltungsanordnung, insbesondere UCP-Flash-Speicher
DE102005030051A1 (de) * 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2010155827A (ja) * 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
CN102361876B (zh) * 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189370A2 (de) * 1985-01-16 1986-07-30 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
EP0205247A2 (en) * 1985-05-10 1986-12-17 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
EP0303391A2 (en) * 1987-08-13 1989-02-15 State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research Optical isomers of a spiroquinuclidine derivative
CN1033629A (zh) * 1987-10-05 1989-07-05 山之内制药株式会社 杂环螺环化合物及其制法
EP0350118A2 (en) * 1988-07-08 1990-01-10 Merck Sharp & Dohme Ltd. Spiro-azabicyclic muscarinic agonists
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
CN1129942A (zh) * 1993-07-20 1996-08-28 以色列国有生物学研究所 作用于胆碱能系统的具有毒蕈碱拮抗性的氮杂螺环化合物
CN1662506A (zh) * 2002-05-03 2005-08-31 以色列生物研究所 治疗中枢和周围神经系统疾病的方法和组合物及其有用的新化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
2-Methyl-1,3-dioxaazaspiro[4.5]decanes as Novel Muscarinic Cholinergic Agonists;John Saunders，等;《Journal of Medicinal Chemistry》;19880229;第31卷(第2期);第486-491页 *

Also Published As

Publication number Publication date
US20110281903A1 (en) 2011-11-17
AU2010207486B2 (en) 2013-03-07
RU2506266C2 (ru) 2014-02-10
AU2010207486A1 (en) 2011-09-15
KR20110127160A (ko) 2011-11-24
BRPI1007350B1 (pt) 2020-11-17
BRPI1007350B8 (pt) 2021-05-25
KR20150116466A (ko) 2015-10-15
KR101675174B1 (ko) 2016-11-10
JP2012515763A (ja) 2012-07-12
CA2750777A1 (en) 2010-07-29
CN102361876A (zh) 2012-02-22
WO2010084499A9 (en) 2010-12-09
EP2389383A2 (en) 2011-11-30
EP2389383B1 (en) 2019-04-24
NZ594768A (en) 2013-02-22
ZA201106221B (en) 2013-04-24
CA2750777C (en) 2018-04-03
BRPI1007350A2 (pt) 2018-03-06
WO2010084499A2 (en) 2010-07-29
JP2015172098A (ja) 2015-10-01
WO2010084499A3 (en) 2010-10-21
RU2011134290A (ru) 2013-03-10
JP5874878B2 (ja) 2016-03-02
US8673931B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
CN102361876B (zh) 二环杂环螺环化合物
CN109661396B (zh) 作为rock抑制剂的螺稠合环状脲
CN109996792B (zh) 在治疗cns疾病和疼痛中具有作为毒蕈碱性m1和/或m4受体调节剂活性的杂环化合物
US11014880B2 (en) Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US9079914B2 (en) Fused aminodihydro-oxazine derivatives
RU2678835C2 (ru) Агонисты мускариновых рецепторов
US11773090B2 (en) Pharmaceutical compounds
US9045499B2 (en) Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9403846B2 (en) Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9034891B2 (en) Bicyclic heterocyclic spiro compounds
EP4436661A1 (en) Spirocyclic cav2.3 antagonists
WO2020207352A1 (zh) 三嗪酮并咪唑类化合物及其医药用途
OA19480A (en) Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives.
HK1249516B (zh) Bace1抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant